Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study

Autor: Su Ching Yang, Chia Tse Weng, Chien Yao Sun, Chun Hsin Wu, Chun Yu Lin, Hung An Chen, Tsai-Ching Hsu
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Adult
Male
medicine.medical_specialty
lcsh:Diseases of the musculoskeletal system
National Health Programs
Hypertension
Pulmonary
Population
Taiwan
Comorbidity
Kaplan-Meier Estimate
Pulmonary arterial hypertension
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Systemic lupus erythematosus
immune system diseases
Internal medicine
polycyclic compounds
Medicine
Humans
Lupus Erythematosus
Systemic
Cumulative incidence
Risk factor
education
skin and connective tissue diseases
Survival rate
Aged
Proportional Hazards Models
030203 arthritis & rheumatology
education.field_of_study
business.industry
Incidence (epidemiology)
Incidence
Hazard ratio
Middle Aged
Prognosis
Confidence interval
Survival Rate
030104 developmental biology
Population Surveillance
Female
lcsh:RC925-935
business
Cohort study
Research Article
Zdroj: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-8 (2019)
Arthritis Research & Therapy
ISSN: 1478-6362
Popis: Background No population-based study has investigated the cumulative incidence of pulmonary arterial hypertension (PAH) in patients with newly diagnosed systemic lupus erythematosus (SLE) or the survival impact of PAH in this population. Method We used a nationwide database in Taiwan and enrolled incident SLE patients between January 1, 2000, and December 31, 2013. The cumulative incidence of PAH in the SLE patients and the survival of these patients were estimated by the Kaplan-Meier method. Potential predictors of the development of PAH were determined using a Cox proportional hazards regression model. Results Of 15,783 SLE patients, 336 (2.13%) developed PAH. The average interval from SLE diagnosis to PAH diagnosis was 3.66 years (standard deviation [SD] 3.36, range 0.1 to 13.0 years). Seventy percent of the patients developed PAH within 5 years after SLE onset. The 3- and 5-year cumulative incidence of PAH were 1.2% and 1.8%, respectively. Systemic hypertension was an independent predictor of PAH occurrence among the SLE patients (adjusted hazard ratio 2.27, 95% confidence interval 1.59–2.97). The 1-, 3-, and 5-year survival rates of SLE patients following the diagnosis of PAH were 87.7%, 76.8%, and 70.1%, respectively. Conclusions PAH is a rare complication of SLE and the majority of PAH cases occur within the first 5 years following SLE diagnosis. Systemic hypertension may be a risk factor for PAH development in the SLE population. The overall 5-year survival rate after PAH diagnosis was 70.1%.
Databáze: OpenAIRE
Externí odkaz: